Skyworks Aeronautics Announces the Order of 100 eGyro™ Electric Aircraft with Options for an Additional 100 by a Consortium of Mint Air and Mobius.energy
Today, Skyworks Aeronautics (“Skyworks”) announces the order of 100 eGyro™ electrically powered vertical take-off and landing (eVTOL) aircraft from a consortium of Mint Air (“Mint”) and Mobius.energy Corp (“Mobius”) with options for an additional 100 aircraft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005323/en/
Notional depiction of the Skyworks eGyro™ (Photo: Business Wire)
“A consortium led by Mint Air is committed to bringing safe, efficient, and cost-effective electric aircraft solutions to South Korea and we are absolutely thrilled they have selected our eGyro as their aircraft of choice to initiate operation of the leading eVTOL service in Korea. We look forward to performing our first public demonstrations of the eGyro in Korea and to launching the eGyro Urban Air Mobility (UAM) platform in the Korean market,” said John Michel, Co-Founder & Executive Director of Skyworks.
“We are pleased to announce the Skyworks eGyro as the launch UAM platform for Mint Air. The fundamental safety and performance advantages of the eGyro will enable Mint Air to accelerate the adoption of intra and inter-city passenger transport in Korea,” said Eugene Choi, Chief Executive Officer of Mint Air.
The consortium led by Mint Air and Skyworks signed a Letter of Intent (LOI) for exclusive partnership in South Korea. The consortium will collaborate with Skyworks to develop a pilot training program and maintenance and repair capability in Korea for efficient operation of eGyro fleet.
The eGyro will leverage Mobius’ novel battery module architecture and low total cost of ownership providing power-as-a-service business model. “The high energy density, unmatched power boost, and outstanding thermal management of the Mobius battery modules support our efforts to produce an aircraft with best-in-class range and performance. We are excited to be the UAM launch platform for the Mobius battery module and service”, said Don Woodbury, Skyworks’ Co-Founder & Chief Technology Advisor.
Jongwon “JP” Park, Chief Strategy Officer and Co-Founder of Mobius said, “Mobius’ is building a global aviation battery alliance and our partnership with Skyworks to bring the eGyro to the Korean market marks an important milestone. Skyworks is the first of many customers who recognized the performance and safety of Mobius’ battery.”
About Mint Air
Mint Air is a startup company in stealth mode until now building an Advanced Air Mobility Service in South Korea. Mint Air’s approach is to facilitate an ecosystem of partners to accelerate the adoption of electric flight in Korea. A former global engineering part manufacturing company, Mint Air will take advantage of its global business experience and network to accelerate the development of the Urban Air Mobility ecosystem in Asia-Pacific markets. Beginning with air taxi operation, Mint Air aspires to become a global electric aircraft manufacturing company building electric aircraft supply chain, developing critical part manufacturing capability, and eventually assembling eGyro in Korea. For more information about the company, visit www.mintair.kr
About Mobius
Mobius.energy is developing safe, light, and energy-efficient novel battery module architecture. The module’s high discharge rate provides on-demand power boost needed during the take-off of electric aircraft at 7C which can last over 6 minutes. Its equally high charge rate enables fast charging in less than 10 minutes. Its light, simple, and compact design enables easy maintenance, on-site swapping, and cost-effective re-use and recycling. Mobius’ goal is to build battery subscription, maintenance, and salvage service including the second life repurpose and the end-of-life recycling of batteries to enable circular economy and thereby contribute to decarbonization of the aviation industry. For more information about the company, visit www.mobius.energy
About Skyworks Aeronautics
Skyworks Aeronautics is the world leader in the science and technology of gyronautics, focusing on the design and development of high-performance gyroplanes. Skyworks gyroplanes provide more affordable, safer, and higher performance alternatives for runway-independent aircraft.
Skyworks has more than 40 patents with several more underway, all obtained in an effort to radically change not only the way gyroplanes are perceived, but also the way they are utilized. From mass personnel transportation, agriculture, defense, and border protection to changing the economies of developing nations, Skyworks' goal is to change the nature of vertical flight. For more information about the company, its products, and individual members of the Skyworks team, visit www.skyworks-aero.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005323/en/
Contact information
Steve G. Stevanovich
steve@skyworks-aero.com
+1 312 809 1076
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 11:53:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 11:00:00 EET | Press release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 11:00:00 EET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom